Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | VAXX | Class A common stock | 51.3M | Nov 10, 2021 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | VAXX | Series A preferred stock | Nov 10, 2021 | Class A common stock | Direct | F2 | ||||||||
holding | VAXX | Series A preferred stock | Nov 10, 2021 | Class A common stock | See Note | F1, F3 | ||||||||
holding | VAXX | Warrant | Nov 10, 2021 | Class A common stock | See Note | F2, F4 |
Id | Content |
---|---|
F1 | Held by United Biomedical, Asia Inc. ("UBIA"). The Reporting Person, through a subsidiary, holds a majority equity interest in UBIA and may be deemed to be the beneficial owner of the shares held by UBIA. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by UBIA in which the Reporting Person has no pecuniary interest. |
F2 | The 384,410 shares of Series A preferred stock will convert into 247,050 shares of Class A common stock automatically upon closing of the initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of Series A preferred stock. |
F3 | The 6,554,643 shares of Series A preferred stock will convert into 4,212,495 shares of Class A common stock automatically upon closing of the initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of Series A preferred stock. |
F4 | Represents 1,928,020 shares of Class A common stock underlying a warrant. The warrant is currently exercisable and has an exercise price of $12.45. |